PD-153035
データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
153436-54-5COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCLSPANGZZENHZNJ-UHFFFAOYSA-NPD-153035 is a member of the class of quinazolines carrying a 3-bromophenylamino substituent at position 4 and two methoxy substituents at positions 6 and 7. It has a role as an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor and an epidermal growth factor receptor antagonist. It is an aromatic amine, an aromatic ether, a member of bromobenzenes, a member of quinazolines and a secondary amino compound. It is a conjugate base of a PD-153035(1+).
153436-54-5化学的特性Yellowish solid
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
Danger
H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]
P264, P264+P265, P270, P280, P301+P316, P305+P354+P338, P317, P321, P330, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 38 reports by companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
使用PD153035 is an inhibitor of EGFR, competitive with ATP. EGF Receptor: IC50 = 25 pM (Ki = 6 pM).
定義ChEBI: A member of the class of quinazolines carrying a 3-bromophenylamino substituent at position 4 and two methoxy substituents at positions 6 and 7.
DTXSID80165328CHEMBL29197CHEBI:91076